A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 2, 2006, Pages 592-602

  Kleiter, Miriam M ^a,b   Thrall, Donald E ^a   Malarkey, David E ^c   Ji, Xiaoshen ^d   Lee, David Y W ^d   Chou, Shu Chuan ^e   Raleigh, James A ^e  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CCI 103F; Differential metabolism; Hypoxia; pH; Pimonidazole

Indexed keywords

BIOMARKERS; BIOPSY; IMMUNOLOGY; METABOLISM; PH EFFECTS; TISSUE;

CCI-103F; DIFFERENTIAL METABOLISM; HYPOXIA; PIMONIDAZOLE;

TUMORS;

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; PIMONIDAZOLE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INVASION; CARCINOMA; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG BINDING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FIBROSARCOMA; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALIGNANT FIBROUS HISTIOCYTOMA; MELANOMA; NERVE SHEATH TUMOR; NONHUMAN; PH; PRIORITY JOURNAL; SARCOMA; TUMOR BIOPSY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CELL HYPOXIA; CELL LINE; CRICETINAE; CRICETULUS; DOG DISEASES; DOGS; FEASIBILITY STUDIES; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; NEOPLASMS; NITROIMIDAZOLES;

EID: 30544449463     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.09.010     Document Type: Article

References (73)

1. J.H. Kaanders, J. Bussink, A.J. van der Kogel Clinical studies of hypoxia modification in radiotherapy Semin Radiat Oncol 14 2004 233 240
2. J.A. Raleigh, G.G. Miller, A.J. Franko Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours Br J Cancer 56 1987 395 400
3. R.E. Durand, J.A. Raleigh Identification of nonproliferating but viable hypoxic tumor cells in vivo Cancer Res 58 1998 3547 3550
4. P.L. Olive, C.M. Luo, J.P. Banath Local hypoxia is produced at sites of intratumour injection Br J Cancer 86 2002 429 435
5. J.M. Cline, D.E. Thrall, R.L. Page Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours Br J Cancer 62 1990 925 931
6. J.M. Cline, D.E. Thrall, G.L. Rosner Distribution of the hypoxia marker CCI-103F in canine tumors Int J Radiat Oncol Biol Phys 28 1994 921 933
7. M.I. Saunders, P.J. Anderson, M.H. Bennett The clinical testing of Ro 03-8799 - pharmacokinetics, toxicology, tissue, and tumor concentrations Int J Radiat Oncol Biol Phys 10 1984 1759 1763
8. J.G. Schwade, J.M. Strong, D.I.V. Gangji misonidazole (NSC 261037). Report of initial clinical experience Cancer Clin Trials 4 1981 33 39
9. C.J. Koch, S.M. Hahn, K. Rockwell Jr Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients Implications for hypoxia measurements in vivo by 2-nitroimidazoles Cancer Chemother Pharmacol 48 2001 177 187
10. C. Azuma, J.A. Raleigh, D.E. Thrall Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime Radiat Res 148 1997 35 42
11. A.S. Kennedy, J.A. Raleigh, G.M. Perez Proliferation and hypoxia in human squamous cell carcinoma of the cervix First report of combined immunohistochemical assays Int J Radiat Oncol Biol Phys 37 1997 897 905
12. M.A. Varia, D.P. Calkins-Adams, L.H. Rinker Pimonidazole A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma Gynecol Oncol 71 1998 270 277
13. J.H. Kaanders, K.I. Wijffels, H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
14. P.L. Olive, C. Aquino-Parsons, S.H. MacPhail Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer Cancer Res 61 2001 8924 8929
15. R.E. Airley, J. Loncaster, J.A. Raleigh GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix Relationship to pimonidazole binding Int J Cancer 104 2003 85 91
16. P.J. Hoskin, A. Sibtain, F.M. Daley GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer Relationship with vascularity and proliferation as predictors of outcome of ARCON Br J Cancer 89 2003 1290 1297
17. J.A. Raleigh, D.P. Calkins-Adams, L.H. Rinker Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker Cancer Res 58 1998 3765 3768
18. J.A. Raleigh, S.C. Chou, D.P. Calkins-Adams A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas Clin Cancer Res 6 2000 855 862
19. H.L. Janssen, K.M. Haustermans, D. Sprong HIF-1alpha, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors Int J Radiat Oncol Biol Phys 54 2002 1537 1549
20. M.O. Arcasoy, K. Amin, S.C. Chou Erythropoietin and erythropoietin receptor expression in head and neck cancer Relationship to tumor hypoxia Clin Cancer Res 11 2005 20 27
21. S.C. Chou, Y. Azuma, M.A. Varia Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas Br J Cancer 90 2004 728 735
22. L.S. Ziemer, C.J. Koch, A. Maity Hypoxia and VEGF mRNA expression in human tumors Neoplasia 3 2001 500 508
23. Y. Azuma, S.C. Chou, R.A. Lininger Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix Pimonidazole and involucrin Clin Cancer Res 9 2003 4944-4452
24. M.S. Wiesener, P.M. Munchenhagen, I. Berger Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas Cancer Res 61 2001 5215 5222
25. S.J. Kwon, Y.J. Lee Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells Clin Cancer Res 11 2005 4694 4700
26. J.M. Cline, G.L. Rosner, J.A. Raleigh Quantification of CCI-103F labeling heterogeneity in canine solid tumors Int J Radiat Oncol Biol Phys 37 1997 655 662
27. D.E. Thrall, G.L. Rosner, C. Azuma Hypoxia marker labeling in tumor biopsies Quantification of labeling variation and criteria for biopsy sectioning Radiother Oncol 44 1997 171 176
28. J.G. Allen, S. Dische, I. Lenox-Smith The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans Eur J Clin Pharmacol 27 1984 483 489
29. K.L. Bennewith, J.A. Raleigh, R.E. Durand Orally administered pimonidazole to label hypoxic tumor cells Cancer Res 62 2002 6827 6830
30. D.E. Thrall, M.C. McEntee, J.M. Cline ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation Int J Radiat Oncol Biol Phys 28 1994 649 659
31. A.S. Ljungkvist, J. Bussink, P.F. Rijken Changes in tumor hypoxia measured with a double hypoxic marker technique Int J Radiat Oncol Biol Phys 48 2000 1529 1538
32. K.L. Bennewith, R.E. Durand Quantifying transient hypoxia in human tumor xenografts by flow cytometry Cancer Res 64 2004 6183 6189
33. A.S. Ljungkvist, J. Bussink, J.H. Kaanders Hypoxic cell turnover in different solid tumor lines Int J Radiat Oncol Biol Phys 62 2005 1157 1168
34. C.E. Smithen, C.R. Hardy The chemistry of nitroimidazole hypoxic cell radiosensitizers A. Breccia C. Rimondi G.E. Adams Advanced topics on radiosensitizers of hypoxic cells 1982 Plenum Press New York 1 47
35. 19F magnetic resonance method for measuring oxygen deficiency in tumors Magn Res Med 22 1991 451 466
36. G.E. Arteel, R.G. Thurman, J.M. Yates Evidence that hypoxia markers detect oxygen gradients in liver Pimonidazole and retrograde perfusion of rat liver Br J Cancer 72 1995 889 895
37. P. Wardman Molecular structure and biological activity of hypoxic cell radiosensitizers and hypoxic specific cytotoxins A. Breccia C. Rimondi G.E. Adams Advanced topics on radiosensitizers of hypoxic cells 1982 Plenum Press New York 49 75
38. J.A. Raleigh, S.C. Chou, G.E. Arteel Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors Radiat Res 151 1999 580 589
39. M.F. Dennis, M.R. Stratford, P. Wardman Cellular uptake of misonidazole and analogues with acidic or basic functions Int J Radiat Biol 47 1985 629 643
40. J.L. Wike-Hooley, J. Haveman, H.S. Reinhold The relevance of tumour pH to the treatment of malignant disease Radiother Oncol 2 1984 343 366
41. J.A. Raleigh, E.M. Zeman, M. Rathman Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor and normal tissue Int J Radiat Oncol Biol Phys 22 1992 403 405
42. L.S. Freedman, P. Workman When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol 22 1988 95 103
43. P. Wardman Lifetimes of the radical-anions of medically-important nitroaryl compounds in aqueous solution Life Chem Rep 3 1985 22 28
44. P.C. Adams, D.E. Rickert Metabolism of [14C]1,3-dinitrobenzene by rat small intestinal mucosa in vitro Drug Metab Dispos 23 1995 982 987
45. J.T. Roberts, N.M. Bleehen, M.I. Walton A clinical phase I toxicity study of Ro 03-8799 Plasma, urine, tumour, and normal brain pharmacokinetics Br J Radiol 59 1986 107 116
46. J.R. Cashman Structural and catalytic properties of the mammalian flavin-containing monooxygenase Chem Res Toxicol 8 1995 166 181
47. V. Lattard, C. Longin-Sauvageon, J. Lachuer Cloning, sequencing, and tissue-dependent expression of flavin-containing monooxygenase (FMO) 1 and FMO3 in the dog Drug Metab Dispos 30 2002 119 128
48. W. Ross Increased sensitivity of Walker tumours towards aromatic nitrogen mustards carrying basic side chains following glucose pretreatment Biochem Pharmacol 8 1961 235 240
49. M.E. Watts, M.F. Dennis, I.J. Roberts Radiosensitization by misonidazole, pimonidazole, and azomycin and intracellular uptake in human tumour cell lines Int J Radiat Biol 57 1990 361 372
50. M. Masana, E.G. de Toranzo, J.A. Castro Reductive metabolism and activation of benznidazole Biochem Pharmacol 33 1984 1041 1045
51. O. Ueda, S. Kitamura, K. Ohashi Xanthine oxidase-catalyzed metabolism of 2-nitrofluorene, a carcinogenic air pollutant, in rat skin Drug Metab Dispos 31 2003 367 372
52. N.M. Hasan, R.B. Cundall, G.E. Adams Effects of hypoxia and reoxygenation on the conversion of xanthine dehydrogenase to oxidase in Chinese hamster V79 cells Free Radic Biol Med 11 1991 179 185
53. H.S. Ozturk, M. Karaayvaz, M. Kacmaz Activities of the enzymes participating in purine and free-radical metabolism in cancerous human colorectal tissues Cancer Biochem Biophys 16 1998 157 168
54. M. Morita, D.R. Feller, J.R. Gillette Reduction of Niridazole by rat liver xanthine oxidase Biochem Pharmacol 20 1971 217 225
55. D. Voshall, D.O. Carr pH dependency of the nonenzymatic oxidation of dihydroflavin by p-nitrobenzoic acid and its methyl ester Biochem Pharmacol 22 1973 1521 1523
56. P. Wardman Protonation of the radical-anions of nitro-imidazole radiosensitizers and the formation of radical-adducts Int J Radiat Biol 28 1975 585 588
57. A.G. Porras, G. Palmer The room temperature potentiometry of xanthine oxidase. pH-dependent redox behavior of the flavin, molybdenum, and iron-sulfur centers J Biol Chem 257 1982 11617 11626
58. T.D. Carson, S.W. Tam-Chang, H.E. Beck Modulating the redox property of a flavin analog through adjustment of its microenvironment in a self-assembled monolayer Antioxid Redox Signal 3 2001 731 736
59. J.A. Raleigh, C.J. Koch Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules Biochem Pharmacol 40 1990 2457 2464
60. C.J. Koch, C.C. Stobbe, K.A. Baer Metabolism induced binding of 14C-misonidazole to hypoxic cells Kinetic dependence on oxygen concentration and misonidazole concentration Int J Radiat Oncol Biol Phys 10 1984 1327 1331
61. C. Miller, L.K. Folkes, C. Mottley Revisiting the interaction of the radical anion metabolite of nitrofurantoin with glutathione Arch Biochem Biophys 397 2002 113 118
62. G. Helmlinger, F. Yuan, M. Dellian Interstitial pH and pO2 gradients in solid tumors in vivo High-resolution measurements reveal a lack of correlation Nat Med 3 1997 177 182
63. J.D. Chapman, K. Baer, J. Lee Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells Cancer Res 43 1983 1523 1528
64. M.W. Gross, U. Karbach, K. Groebe Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids Int J Cancer 61 1995 567 573
65. M.W. Dewhirst, R.D. Braun, J.L. Lanzen Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats Int J Radiat Oncol Biol Phys 42 1998 723 726
66. 2-dependence of metabolism Adv Exp Med Biol 222 1988 143 151
67. I.J. Hoogsteen, H.A. Marres, K.I. Wijffels Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma Clin Cancer Res 11 2005 97 106
68. L. Du, S.M. Hoffman, D.S. Keeney Epidermal CYP2 family cytochromes P450 Toxicol Appl Pharmacol 195 2004 278 287
69. J.A. Raleigh, D.E. Thrall, M.A. Varia Development and clinical application of pimonidazole as a marker for tumor hypoxia Recent Res Devel Cancer 3 2001 189 201
70. S.M. Evans, S. Hahn, D.R. Pook Detection of hypoxia in human squamous cell carcinoma by EF5 binding Cancer Res 60 2000 2018 2024
71. J. Bussink, J.H. Kaanders, P.F. Rijken Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line Radiat Res 153 2000 398 404
72. H.W. van Laarhoven, J. Bussink, J. Lok Effects of nicotinamide and carbogen in different murine colon carcinomas Immunohistochemical analysis of vascular architecture and microenvironmental parameters Int J Radiat Oncol Biol Phys 60 2004 310 321
73. K.L. Bennewith, R.E. Durand Quantifying transient hypoxia in human tumor xenografts by flow cytometry Cancer Res 64 2004 6183 6189